Nanjing Bioheng Biotech Co., Ltd.   Report issue

For profit Phase 1
Founded: Nanjing China (2017)

Organization Overview

First Clinical Trial
2019
NCT04026100
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Nanjing Bioheng Biotech Co., Ltd.

Active Ingredients

Drugs in Phase 1 Trials (5)

cd19 car-t cells (3 trials)

cta30x (1 trial)

cta30x ucar-t (1 trial)

ct-rd06 (1 trial)

rd13-01 (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hematologic Neoplasms (Phase 1)

Leukemia (Phase 1)

Leukemia, Lymphoid (Phase 1)

Lymphoma (Phase 1)

Lymphoma, B-Cell (Phase 1)

Lymphoma, Large B-Cell, Diffuse (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 11
  • # of Trial APIs: 5